Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea

Fineline Cube Apr 9, 2026
Company Deals

Grand Pharma Partners with HKU on Anti‑Infective Drug Discovery – Exclusive License Deal Targets Novel Antibacterial Therapies

Fineline Cube Apr 9, 2026
Company Deals

Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests

Fineline Cube Apr 8, 2026
Company Deals

Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline

Fineline Cube Apr 8, 2026
Company Deals

Biogen Licenses Alloy Therapeutics’ AntiClastic ASO Platform to Advance Next-Generation Antisense Therapy Research

Fineline Cube Apr 8, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Fineline Cube Apr 9, 2026
Company Drug

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Fineline Cube Apr 9, 2026
Company Deals

China Grand Pharmaceutical to Acquire Majority Stake in Mitsubishi Tanabe’s Tianjin Subsidiary

Fineline Cube Dec 22, 2023

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced its intention to...

Company Medical Device

Beijing Balance Medical Secures NMPA Approval for Innovative Mitral Valve Annuloplasty Ring

Fineline Cube Dec 22, 2023

Beijing Balance Medical Technology Co., Ltd (SHA: 688198), a Chinese medical device company, has received...

Company Deals

Beijing Strong Biotechnologies Strikes Distribution Deal with ELITechGroup for Immunohistochemical Staining Systems

Fineline Cube Dec 22, 2023

Beijing Strong Biotechnologies Inc., (SHE: 300406) a Chinese company, has entered into a product distribution...

Company Deals

Sanofi Broadens Collaboration with Exscientia, Licensing New Precision Drug Program

Fineline Cube Dec 22, 2023

French pharmaceutical giant Sanofi (NASDAQ: SNY) has expanded its partnership with UK-based AI-driven precision drug...

Company Drug

AstraZeneca Advances to Phase III with PD-1xTIGIT BsAb for Biliary Tract Cancer

Fineline Cube Dec 21, 2023

AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical company, is set to initiate a Phase III...

Company Drug

Lee’s Pharmaceutical’s Socazolimab Becomes China’s First PD-L1 mAb for Cervical Cancer

Fineline Cube Dec 21, 2023

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has secured in-licensed rights for socazolimab, a treatment for...

Company Deals

Zhiyi Biotechnology and Henlius Biotech Partner to Develop Novel Drug Products and Platforms

Fineline Cube Dec 21, 2023

Guangzhou-based Zhiyi Biotechnology has entered into a strategic partnership with Shanghai Henlius Biotech Inc. (HKG:...

Company Drug

FDA Rejects MSD’s Gefapixant for Chronic Cough Treatment Over Efficacy Concerns

Fineline Cube Dec 21, 2023

The US Food and Drug Administration (FDA) has declined to approve a filing from Merck,...

Company Deals

Shanghai Novopathway and PONY Biomedicine Join Forces for Pre-Clinical Drug Development Platform

Fineline Cube Dec 21, 2023

Shanghai Novopathway Biotechnology, a Chinese biopharmaceutical company, has entered into a strategic partnership with fellow...

Company Deals

GSK Secures Exclusive Rights to Hansoh’s ADC Candidate HS-20093 in New Licensing Deal

Fineline Cube Dec 21, 2023

GlaxoSmithKline (GSK; NYSE: GSK), a major UK pharmaceutical company, has entered into its second licensing...

Company Deals

3SBio Partners with HQ Pharma to Develop and Commercialize Eltrombopag Olamine Dry Suspension

Fineline Cube Dec 21, 2023

3SBio Inc., (HKG: 1530), a leading biopharmaceutical company based in China, has entered into a...

Company Medical Device

Zylox-Tonbridge Completes Patient Enrollment for ZENFLEX Study in Germany

Fineline Cube Dec 21, 2023

Zylox-Tonbridge Medical Technology (HKG: 2190), a China-based developer of nerve and peripheral vascular interventional devices,...

Company Drug

Jiangsu Hengrui Pharmaceuticals Wins NMPA Approvals for SLE and Lymphoma Drug Candidates

Fineline Cube Dec 21, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has announced that...

Company Drug

RemeGen’s Telitacicept Secures FDA Approval for Global Phase III Study in Primary Sjogren’s Syndrome

Fineline Cube Dec 21, 2023

RemeGen (HKG: 9995), a China-based pharmaceutical company, has received approval from the US Food and...

Company

Novo Nordisk Foundation Launches $260 Million Initiative to Develop Respiratory Disease Vaccines

Fineline Cube Dec 21, 2023

Novo Nordisk Foundation, the entity that controls Denmark-based Novo Nordisk (CPH: NOVO-B), has unveiled an...

Company Deals

LianBio Board Turns Down Concentra Biosciences Buyout Offer

Fineline Cube Dec 20, 2023

China-based LianBio (OTCMKTS: LIANY) has announced that its board of directors has unanimously decided not...

Company Deals

Gilead Acquires Pre-Clinical IL-18BP Targeting Antibody Candidate from Compugen in $848 Million Deal

Fineline Cube Dec 20, 2023

Gilead (NASDAQ: GILD) has licensed a potential first-in-class IL-18 binding protein (IL-18BP) targeting antibody candidate...

Company Deals

Jiangsu Synthgene and Starna Therapeutics Join Forces in mRNA Technology Advancement

Fineline Cube Dec 20, 2023

China’s Jiangsu Synthgene Biotechnology Co., Ltd has announced a strategic partnership with Suzhou-based Starna Therapeutics,...

Company Deals

Shanghai Escugen Partners with InxMed for Global Development Rights to EZWi-Fit Platform

Fineline Cube Dec 20, 2023

Shanghai Escugen has entered into a partnership with InxMed (Nanjing) Co., Ltd, granting the Chinese...

Company Drug

RemeGen Ltd Receives FDA Clearance for MSLN-Targeting ADC RC88 in Gynecological Tumors

Fineline Cube Dec 20, 2023

China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has announced that it has received clinical clearance...

Posts pagination

1 … 408 409 410 … 648

Recent updates

  • Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China
  • Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia
  • Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies
  • GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer
  • Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Company Drug

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Company Drug

Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies

Company Drug

GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.